Article
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Molecular cancer research : MCR - 1 Jul 2017
Yamaoka Toshimitsu, Ohmori Tohru, Ohba Motoi, Arata Satoru, Murata Yasunori, Kusumoto Sojiro, Ando Koichi, Ishida Hiroo, Ohnishi Tsukasa, Sasaki Yasutsuna
Abstract excerpt
EGFR tyrosine kinase inhibitors (TKI) are associated with significant responses in non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations. However, acquired resistance to reversible EGFR-TKIs remains a major obstacle. In particular, although the second-generation irreversible EGFR-TKI afatinib is currently used for treating NSCLC patients, the mechanisms underlying acquired afatinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.